Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
October 31, 2023 07:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended...
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
October 18, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
October 17, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Publication in Cancers
October 16, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
September 21, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Participate at Upcoming Investor Conferences in September
September 06, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 10, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
Q2 2023 DANYELZA® record net product revenues of $20.8 million, driving YoY growth of 112% and a 3% sequential increase compared to Q1 2023Management reiterates FY 2023 financial guidanceDANYELZA...
Y-mAbs to Participate at Upcoming Investor Conferences
August 02, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
August 01, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter...
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
May 26, 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...